<DOC>
	<DOCNO>NCT01394952</DOCNO>
	<brief_summary>The purpose trial ass whether dulaglutide reduce major cardiovascular event serious outcome person type 2 diabetes , add anti-hyperglycemic regimen .</brief_summary>
	<brief_title>Researching Cardiovascular Events With Weekly Incretin Diabetes ( REWIND )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Type 2 diabetes Hemoglobin A1c equal less 9.5 % ( equal less 81 mmol/mol ) Antihyperglycemic drug naive treat 2 oral hyperglycemic drug without glucagonlike peptide1analog basal insulin , basal insulin alone On stable antihyperglycemic regimen least 3 month Age equal great 50 year establish clinical vascular disease , age equal great 55 year subclinical vascular disease age equal great 60 year least 2 cardiovascular risk factor Uncontrolled diabetes require immediate therapy History severe hypoglycemia past year Acute coronary cerebrovascular event within past 2 month Planned anticipated revascularization procedure History pancreatitis , hepatic insufficiency , chronic renal failure Ccell thyroid disorder Pregnancy plan pregnancy trial period Completed withdrawn study investigate dulaglutide</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Dulaglutide</keyword>
</DOC>